This is a working overview of visceral adiposity, written for readers who want more than a one-paragraph summary but less than a textbook.
Reviewed 2025-10-24. Anything still debated is marked as such rather than presented as settled.
Tesamorelin is a synthetic analog of growth hormone-releasing hormone, a peptide hormone produced by the hypothalamus. The molecule retains the 44-amino-acid sequence of human GHRH and carries a trans-3-hexenoyl modification at its N-terminus. This modification increases resistance to enzymatic degradation and extends the peptide's functional stability relative to native GHRH. The compound is supplied as a lyophilized powder for reconstitution and subcutaneous administration in clinical settings. Its development code was TH9507, and it belongs to the GHRH analog class. It is not a growth hormone product; instead, it acts upstream to stimulate endogenous growth hormone release.
Clinical interest in tesamorelin arose from the need to address visceral adiposity in people living with HIV. Antiretroviral therapy improved survival but was associated in some patients with central fat accumulation, altered lipid profiles, and metabolic complications. This condition, often called HIV-associated lipodystrophy, involves excess visceral adipose tissue that is difficult to manage through diet and exercise alone. Investigators evaluated tesamorelin because GHRH analogs can stimulate growth hormone secretion and influence fat distribution without direct liposuction or invasive procedures.
A Phase 3 program led to regulatory approval in the United States in 2010 for reduction of excess visceral abdominal fat in adults with HIV and lipodystrophy. Subsequent studies examined effects on liver fat, muscle area, and metabolic markers, with mixed findings for some endpoints. Long-term cardiovascular outcomes and effects on mortality remain uncertain because most trials were relatively short and focused on imaging-based fat measurements. Use in populations without HIV has been studied experimentally but is not part of the approved indication.
Tesamorelin is a synthetic peptide built from 44 amino acids and classified with the growth hormone–releasing hormone family. Its sequence corresponds to the human GHRH(1-44) backbone, carrying one structural change at the amino terminus. That change is a trans-3-hexenoyl group placed where the natural peptide would have an unmodified end. The modification is the feature that separates the compound from the endogenous hormone in name, in stability, and in how it is handled in the laboratory.
The hexenoyl cap slows the enzyme step that trims the amino terminus of native GHRH, the same step that shortens its active lifetime in circulation. As a result, the modified peptide persists longer in plasma than the unmodified hormone in side-by-side comparison. Receptor activity stays broadly comparable, because the added group sits away from the residues that contact the binding site. This combination, preserved receptor activity with reduced degradation, explains why the analog was developed instead of the native sequence.
| Property | Value | Notes |
|---|---|---|
| Molecular weight | Approximately 5,136 Da | Based on the 44-amino-acid peptide backbone and N-terminal modification. |
| Appearance | White to off-white lyophilized powder | Usually supplied in single-use vials for reconstitution. |
| Solubility | Freely soluble in water; slightly soluble in some organic solvents | Peptide nature supports aqueous reconstitution. |
| Typical storage | 2–8 °C, protected from light | Refrigeration reduces degradation; avoid freezing unless specified. |
| Common analytical method | Reverse-phase high-performance liquid chromatography | Used for identity, purity, and quantification. |
| Synonyms | Tesamorelin, TH9507, GHRH(1-44) analog | Generic descriptors; avoid proprietary names. |
Tesamorelin is a synthetic peptide of 44 amino acids that reproduces the sequence of human growth hormone-releasing hormone (GHRH) and carries a trans-3-hexenoyl group on its N-terminal tyrosine. That small fatty-acid modification blocks cleavage by dipeptidyl peptidase-4, the enzyme that rapidly degrades native GHRH in plasma. The result is a molecule with a longer circulating half-life than the natural hormone while retaining the same receptor target. It is supplied as a lyophilized powder for reconstitution and belongs to the broader class of GHRH analogs studied for effects on pituitary growth hormone secretion.
Development work on the compound, originally designated TH9507, focused on conditions in which reduced growth hormone signaling is thought to contribute to altered body composition. The United States Food and Drug Administration approved it in 2010 for the treatment of excess visceral abdominal fat in adults with human immunodeficiency virus infection and lipodystrophy. Later research examined other populations, including adults with mild cognitive impairment, where a large trial did not meet its primary endpoints. This mixed record illustrates how a single mechanism can produce clear effects in one setting and inconclusive results in another.
Interest in this peptide developed because native GHRH has a short circulating lifetime. The N-terminal modification slows cleavage by dipeptidyl peptidase IV, an enzyme that removes the first two residues of many peptides and terminates their activity. Slower degradation means a longer window of receptor stimulation per administration. This design logic parallels other modified peptide hormones, where a small chemical change at a vulnerable site yields a more durable molecule without altering the core mechanism of action.
The peptide is synthesized chemically rather than extracted from biological sources. Solid-phase synthesis builds the chain from the C-terminus toward the N-terminus, after which the hexenoyl group is attached. Purity is typically assessed by high-performance liquid chromatography, and identity is confirmed by mass spectrometry. Regulatory review of the finished product focuses on these analytical controls, since small deviations in sequence or modification can change biological activity. Questions about long-term effects on the pituitary axis remain areas of continued investigation.
Clinical study of tesamorelin has centered on adults with HIV-associated lipodystrophy, a condition in which abdominal fat accumulates while peripheral fat is lost. In controlled trials, treated participants showed reductions in visceral adipose tissue measured by imaging, alongside modest shifts in some lipid values. Effects on subcutaneous fat were smaller and less consistent across studies. Whether these changes translate into fewer cardiovascular events remains an open question, because the trials were not designed or powered to answer it.
Tesamorelin is a synthetic peptide that acts as an analog of growth hormone-releasing hormone, a natural hypothalamic signal. Its sequence corresponds to the forty-four amino acid form of the human hormone, with a small acyl group attached near the amino terminus. That modification slows enzymatic breakdown and extends the time the peptide remains active in circulation. The compound was developed as a pharmacological way to raise endogenous growth hormone output rather than supplying the hormone directly.
After injection, the peptide binds receptors on somatotroph cells in the anterior pituitary. Receptor activation raises intracellular cyclic AMP and triggers release of stored growth hormone into the bloodstream. Because the compound works through the body's own regulatory system, growth hormone pulses retain much of their normal feedback control. Repeated administration also raises insulin-like growth factor 1, a hormone produced mainly in the liver. Investigators treat that rise as a marker that the pituitary axis has been engaged.
=== Solvent/detergent (S/D) inactivation === This process, developed by the New York Blood Center, is the most widely used viral inactivation method to date. It is predominantly used in the blood plasma industry, by over 50 organizations worldwide and by the American Red Cross. This process is only effective for viruses enveloped in a lipid coat, however. The detergents used in this method interrupt the interactions between the molecules in the virus's lipid coating. Most enveloped viruses cannot exist without their lipid coating so are destroyed when exposed to these detergents. Other viruses may not be destroyed but they are unable to reproduce rendering them non-infective. The solvent creates an environment in which the aggregation reaction between the lipid coat and the detergent happen more rapidly. The detergent typically used is Triton X-100. This process has many of the advantages of the "traditional" removal techniques. This process does not denature proteins, because the detergents only affect lipids and lipid derivatives. There is a 100% viral death achieved by this process and the equipment is relatively simple and easy to use. Equipment designed to purify post-virus inactivated material would be necessary to guard against contamination of subsequent process streams. S/D treatment utilizes readily available and relatively inexpensive reagents, but these reagents must be removed from the product prior to distribution which would require extra process steps.
== Chemistry == ETH-LAD, also known as 9,10-didehydro-N,N,6-triethylergoline-8β-carboxamide or as 6-ethyl-6-nor-LSD, is a substituted lysergamide derivative related to lysergic acid diethylamide (LSD; also known as METH-LAD). It is the 6-ethyl derivative of nor-LSD (6-nor-LSD; H-LAD) and is the derivative of LSD with an ethyl group instead of methyl group at the 6 position of the ergoline ring system.
== Stability == All of the known 251 stable nuclides, plus another 35 nuclides that have half-lives long enough to have survived from the formation of the Earth, occur as primordial nuclides. These 35 primordial radionuclides represent isotopes of 28 separate elements. Cadmium, tellurium, xenon, neodymium, samarium, osmium, and uranium each have two primordial radioisotopes (113Cd, 116Cd; 128Te, 130Te; 124Xe, 136Xe; 144Nd, 150Nd; 147Sm, 148Sm; 184Os, 186Os; and 235U, 238U). Because the age of the Earth is 4.58×109 years (4.58 billion years), the half-life of the given nuclides must be greater than about 108 years (100 million years) for practical detectability. For example, for a nuclide with half-life 6×107 years (60 million years), this means 77 half-lives have elapsed, meaning that for each mole (6.02×1023 atoms) of that nuclide being present at the formation of Earth, only 4 atoms remain today. The seven shortest-lived primordial nuclides (i.e., the nuclides with the shortest half-lives) to be detected as primordial are 87Rb (4.92×1010 years), 187Re (4.12×1010 years), 176Lu (3.70×1010 years), 232Th (1.40×1010 years), 238U (4.46×109 years), 40K (1.25×109 years), and 235U (7.04×108 years). These are the seven nuclides with half-lives comparable to, or somewhat less than, the estimated age of the universe. (87Rb, 187Re, 176Lu, and 232Th have half-lives somewhat longer than the age of the universe.) For practical purposes, nuclides with half-lives much longer than the age of the universe may be treated as if they were stable.
Sources: en.wikipedia.org
== Safety == DNCB induces a type IV hypersensitivity reaction in almost all people exposed to it, so it is used medically to assess the T cell activity in patients. This is a useful diagnostic test for immunocompromised patients. It can also be used to treat warts. DNCB can cause contact dermatitis.
On August 31, 2022, FIFA president Gianni Infantino confirmed that six CONCACAF teams would qualify for the World Cup, with Canada, Mexico, and the United States automatically qualifying as hosts. This was confirmed by the FIFA Council on February 14, 2023. Immediately prior to the 67th FIFA Congress, the FIFA Council approved the slot allocation during a meeting in Manama, Bahrain. This included an inter-confederation playoff tournament involving six teams to decide the last two FIFA World Cup spots. The six teams in the playoffs comprised one team from each confederation excluding UEFA, and one additional team from the confederation of the host countries (CONCACAF). Two of those teams were seeded based on the World Rankings, and they played the winners of two knockout matches between the four unseeded teams for the two FIFA World Cup berths. The four-match tournament was played in Mexico, one of the host countries, and was also used as a test event for the FIFA World Cup. The ratification of slot allocation also gave the OFC a guaranteed berth in the final tournament for the first time: the 2026 FIFA World Cup was the first tournament in which all six confederations had at least one guaranteed berth and also the first time since the 2010 edition in which all confederations had a team qualify for the World Cup finals. Of the 48 qualified teams, 26 also appeared in the 2022 edition. Highlights include:
=== Lawsuit === Fenn's work with electrospray ionization was at the center of a lawsuit pitting him against his alma mater and former employer, Yale University. His initial dispute with the university began in 1987, when he turned 70 – Yale's mandatory retirement age. Per university policy, Fenn was made an emeritus professor, which resulted in a reduction to his lab space. Emeritus professors at Yale are still provided with an office, but cannot conduct their own research, nor manage their own labs. In 1989, when Yale University inquired about the progress and potential about his electrospray work, he downplayed its potential scientific and commercial value. Fenn believed he had the rights to the invention under the Bayh–Dole Act. Fenn patented the technology on his own, and sold licensing rights to a company he partly owned – Analytica of Branford. In 1993, a private company seeking to license the use of electrospray technology traced its invention to Yale, when the university discovered that Fenn held the patent. Yale's policy regarding patents generated by faculty or students requires that a percentage of any royalties generated from the patent are used by the university to fund future research. They do not claim the rights to patents that are produced away from university facilities or not related to the researcher's "designated activities." Fenn claimed that he owned the technology because the work was completed after he had been forced to downsize at the university's mandatory retirement age.
Sources: en.wikipedia.org
It is hypothesized to function by changing its lowest luminescent state from n–π* to π–π* when coordinating to a metal. When the Dansyl group DNS binds to a metal, it loses a sulfonamide hydrogen, causing fluorescence quenching via a PET or reverse PET mechanism in which an electron is transferred either to or from the metal that is bound. Small molecule sensors for zinc have been reported. One example is "ZX1", a compound comprising a dipicolylamine (DPA) Zinc binding subunit that has greater affinity for Zinc than other species found in solution such as Ca and Mg. GFZnP OMe is an alternate, GFP-based fluorescent Zn2+ sensor is published for two-photon microscopy and related biological and microscop application. It composed of an 8-methoxyquinoline scaffold. It has excellent photophysical characteristics including a 37-fold fluorescence enhancement with l(ex) = 440 nm and l(em) = 505 nm. The two-photon cross-section is as high as 73 GM at 880 nm. GFZnP BIPY features a 2,2'-bipyridine chelator moiety. It was effective at physiologically relevant pH-range and excellent photophysical characteristics are reported, including a 53-fold fluorescence enhancement with excitation and emission maxima at 422 nm and 492 nm, respectively. High two-photon cross-section of 3.0 GM at 840 nm as well as excellent metal ion selectivity are reported. In vitro experiments on HEK 293 cell culture were carried out using two-photon microscopy demonstrating the applicability.
Continuous positive airway pressure (CPAP) is effective for both moderate and severe disease. It is the most common treatment for obstructive sleep apnea. Variable positive airway pressure (VPAP) (also known as bilevel (BiPAP or BPAP)) uses an electronic circuit to monitor the patient's breathing and provides two different pressures, a higher one during inhalation and a lower pressure during exhalation. This system is more expensive and is sometimes used with patients who have other coexisting respiratory problems or who find breathing out against an increased pressure to be uncomfortable or disruptive to their sleep. Nasal EPAP, which is a bandage-like device placed over the nostrils that utilizes a person's own breathing to create positive airway pressure to prevent obstructed breathing. Automatic positive airway pressure, also known as "Auto CPAP", incorporates pressure sensors and monitors the person's breathing. A 5% reduction in weight among those with moderate to severe OSA may decrease symptoms similarly to CPAP. Encouraging people with moderate to severe OSA to use CPAP devices can be challenging, as their use often requires a behavioural change in sleeping habits. 8% of people who use CPAP devices stop using them after the first night, and 50% of people with moderate to severe OSA stop using their devices in the first year. Educational initiatives and supportive interventions to help improve compliance with CPAP therapy have been shown to improve the length of time people who need CPAP therapy use their devices.
The outermost wall of the organ is known as the parietal layer The skin of the organ is known as the visceral layer. The organs have specialized names for their visceral fasciae. In the brain, they are known as meninges; in the heart they are known as pericardia; in the lungs, they are known as pleurae; and in the abdomen, they are known as peritonea. Visceral fascia is less extensible than superficial fascia. Due to its suspensory role for the organs, it needs to maintain its tone rather consistently. If it is too lax, it contributes to organ prolapse, yet if it is hypertonic, it restricts proper organ motility.
=== Kinetically frozen micelles === When block copolymer micelles do not display the characteristic relaxation processes of surfactant micelles, these are called kinetically frozen micelles. These can be achieved in two ways: when the unimers forming the micelles are not soluble in the solvent of the micelle solution, or if the core forming blocks are glassy at the temperature in which the micelles are found. Kinetically frozen micelles are formed when either of these conditions is met. A special example in which both of these conditions are valid is that of polystyrene-b-poly(ethylene oxide). This block copolymer is characterized by the high hydrophobicity of the core forming block, PS, which causes the unimers to be insoluble in water. Moreover, PS has a high glass transition temperature which is, depending on the molecular weight, higher than room temperature. Thanks to these two characteristics, a water solution of PS-PEO micelles of sufficiently high molecular weight can be considered kinetically frozen. This means that none of the relaxation processes, which would drive the micelle solution towards thermodynamic equilibrium, are possible. Pioneering work on these micelles was done by Adi Eisenberg. It was also shown how the lack of relaxation processes allowed great freedom in the possible morphologies formed. Moreover, the stability against dilution and vast range of morphologies of kinetically frozen micelles make them particularly interesting, for example, for the development of long circulating drug delivery nanoparticles.
Sources: en.wikipedia.org
It is a synthetic peptide analog of human growth hormone-releasing hormone. It is used clinically to reduce excess visceral abdominal fat in adults with HIV-associated lipodystrophy. It works by stimulating pituitary growth hormone release.
Pivotal trials enrolled adults with HIV and excess visceral abdominal fat, often in the context of antiretroviral therapy. Participants were assessed mainly by computed tomography for visceral adipose tissue. The approved indication remains specific to that population.
Long-term effects on cardiovascular events, mortality, and sustained fat distribution are not well established. Most trials measured changes over months rather than years. Open questions also include whether benefits persist after treatment stops.
No. It is a peptide that acts upstream of growth hormone release, while growth hormone is the hormone itself. The two differ in size, in receptor, and in how the body clears them.